ニュース本文
Central News(Central News Agency Reporter He Xiuling Taipei 26th) PharmaEngine announced that its independently developed and produced innovative long-acting interferon, the new drug Ropeg for rare blood cancer in a pen injector, has been approved by the U.S. Food and Drug Administration (FDA) and will be launched in the United States within a few weeks. It is expected to strengthen the Ropeg product line layout and add new momentum to sales growth in the U.S. market.PharmaEngine stated in a press release today that it has completed the commercial mass production and supply chain preparations for the Ropeg pen injector in advance, ensuring that the product can be quickly introduced to the market after approval.Ropeg was approved by the US FDA in November 2021 for adult patients with polycythemia vera (PV). It is currently applying for drug approval review for the new indication of essential thrombocythemia (ET). PharmaEngine explained that the US FDA has notified that the target date for the completion of the drug approval review is August 30th of this year.PharmaEngine stated that with stable revenue contributions from the existing indication PV market, clear progress in the new indication ET drug approval review, and the expected increase in market penetration after the launch of the pen injector, the company is expected to enter a new phase of accelerated operational growth this year. (Editor: Pan Yijing) 1150626Choose to stand with the facts. Every contribution you make is a force to protect press freedom.Download the Central News Agency "Firsthand News" APP to grasp the latest news in real-time.No reproduction, public broadcast, public transmission, or use of the text, images, and videos on this website is permitted without authorization.